{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Abbreviation or Specialist Term', 'Explanation', 'ET', 'Early termination', 'FIX', 'Factor IX', 'FV', 'Factor V', 'FVII', 'Factor VII', 'FVIII', 'Factor VIII', 'FX', 'Factor X', 'GalNAc', 'N-acetylgalactosamine', 'GCP', 'Good Clinical Practice', 'GGT', 'Gamma glutamyl transferase', 'GLP', 'Good Laboratory Practice', 'HAL', 'Hemophilia Activities List', 'Haem-A-QOL', 'Hemophilia Quality of Life Questionnaire for Adults', 'Haemo-QOL', 'Hemophilia Quality of Life Questionnaire for children and', 'adolescents', 'HBc Ab', 'Hepatitis B core antibody', 'HBs Ag', 'Hepatitis B surface antigen', 'HIV', 'Human immunodeficiency virus', 'HRQOL', 'Health-related quality of life', 'IB', \"Investigator's Brochure\", 'ICF', 'Informed consent form', 'ICH', 'International Conference on Harmonisation', 'IEC', 'Independent Ethics Committee', 'IMP', 'Investigational medicinal product', 'INR', 'International normalized ratio', 'IP', 'Investigational product', 'IRB', 'Institutional Review Board', 'IRS', 'Interactive response system', 'ISR', 'Injection site reaction', 'ITT', 'Intent-to-treat', 'ISTH', 'International Society on Thrombosis and Hemostasis', 'ITI', 'Immune tolerance induction', 'IV', 'Intravenous', 'LFT', 'Liver function test', 'Property of the Sanofi Group - strictly confidential', '24']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Abbreviation or Specialist Term', 'Explanation', 'MAD', 'Multiple ascending dose', 'MDRD', 'Modification of Diet in Renal Disease', 'MMRM', 'Mixed effect repeated measures', 'mRNA', 'Messenger ribonucleic acid', 'NHP', 'Non-human primates', 'NOAEL', 'No observed adverse effect level', 'PD', 'Pharmacodynamics', 'PedHAL', 'Pediatric HAL', 'PK', 'Pharmacokinetics', 'PP', 'Per-protocol', 'PT', 'Prothrombin time', 'QOL', 'Quality of Life', 'RNAi', 'Ribonucleic acid interference', 'rVIIa', 'Recombinant factor VIIa', 'SAD', 'Single ascending dose', 'SAE', 'Serious adverse event', 'SAP', 'Statistical Analysis Plan', 'SC', 'Subcutaneous', 'SD', 'Standard deviation', 'SDay', 'Surgery day', 'siRNA', 'Small interfering ribonucleic acid', 'SSC', 'Scientific Standardization Committee', 'SUSAR', 'Suspected unexpected serious adverse reactions', 't1/2B', 'Elimination half-life', 'tmax', 'Time to maximum plasma concentration', 'TG', 'Thrombin generation', 'TSQM', 'Treatment Satisfaction Questionnaire for Medication', 'ULN', 'Upper limit of normal', 'V/F', 'Apparent volume of distribution', 'Property of the Sanofi Group - strictly confidential', '25']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '1.', 'INTRODUCTION', '1.1.', 'Disease Overview', 'Hemophilia A and hemophilia B are X-linked recessive inherited bleeding disorders,', 'characterized by deficiency of coagulation factors VIII (FVIII) or factor IX (FIX), leading to a', 'profound defect of thrombin generation with impaired hemostasis and increased risk of bleeding.', 'Hemophilia A is found in approximately 1 in 5000 males whereas hemophilia B is five times less', 'common and seen in approximately 1 in 25,000 males.| The disease affects all ethnicities and', 'the mutation responsible for hemophilia is typically inherited from a carrier parent, although', 'spontaneous mutations are responsible for ~30% of all cases [1]', 'The disease phenotype presents similarly in hemophilia A and B.[2] Hemophilia is classified as', 'mild (factor levels 6% to 30%), moderate (factor levels 1% to 5%), or severe (factor levels <1%)', 'based on clotting factor activity relative to normal (healthy, non-hemophiliac plasma levels of', 'factor are 50% to 150%). Patients with mild hemophilia typically experience bleeding after a', 'serious injury or surgery; patients with moderate hemophilia experience bleeding episodes', 'associated with injuries, and may have spontaneous bleeding episodes; severe hemophilia', 'patients experience substantial bleeding with injury and may have frequent spontaneous bleeding', \"episodes resulting in debilitating musculoskeletal damage that can markedly impair a patient's\", 'mobility and quality of life (QOL).', 'The hemostatic system aims to maintain the integrity of the vasculature by protecting against', 'bleeding from vessel lesions combined with multiple options to prevent thrombosis. This', 'hemostatic balance is achieved through an orchestrated regulation of both procoagulant (eg,', 'factor V [FV], factor VII [FVII], FVIII, FIX, factor X [FX]) and anticoagulant (eg, antithrombin', '(AT), protein C/protein S and tissue factor pathway inhibitor) factors. Recent studies have', 'suggested that coinheritance of a deficiency in natural anticoagulants may contribute to a milder', 'phenotype in patients with hemophilia. Antithrombin is a liver-expressed natural anticoagulant', 'that plays a key role in inhibiting thrombin. Furthermore, AT acts as an inhibitor of FVIIa and', 'FXa, which are typically at normal levels in patients with hemophilia A or B. Extensive', 'preclinical in vitro and in vivo studies have described reduction of AT as a potential safe and', 'effective way to correct thrombin generation in both hemophilia A and B and control against', 'microvascular and macrovascular traumatic bleeding episodes. [3] Therefore, suppression of AT', 'production is being investigated as a potential hemophilia treatment.', 'Hemophilia patients who develop inhibitory antibodies to FVIII or FIX represent a distinct', 'subset of the population; these patients typically experience more difficult-to-treat bleeding', 'episodes, leading to increased morbidity and increased mortality.[ [4] In 20% to 33% of patients', 'with hemophilia A, inhibitory antibodies form to FVIII; in hemophilia B, 1% to 6% of patients', 'develop inhibitory antibodies to FIX.[5] These \"inhibitor\" patients, may be eligible for immune', 'tolerance therapy, however in most cases bleeding episodes require hemostatic intervention with', 'intravenously administered bypassing agents (BPAs), either as prophylaxis or as on-demand', 'episodic treatment of bleeding episodes, ie, recombinant factor VIIa (rVIIa), or activated', 'prothrombin complex concentrates (aPCC).', 'Property of the Sanofi Group - strictly confidential', '26']\n\n###\n\n", "completion": "END"}